Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
All the vital news, analysis, and commentary curated by our industry experts.
Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Report Overview
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. Influenza infection is normally self-limiting. Symptoms generally last for one to two weeks, but most people infected with influenza do not need or seek medical treatment.
The Seasonal Influenza Therapeutics (SIT) marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in SITs. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for SITs.
Leading Marketed Drugs for SIT
Some of the leading marketed drugs for influenza are baloxavir marboxil, zanamivir, oseltamivir phosphate, favipiravir, ribavirin, rimantadine hydrochloride, umifenovir, laninamivir, thymalfasin, and peramivir. The majority of the marketed drugs for the treatment of influenza are exo alpha sialidase inhibitors.
SIT Marketed Drugs Segmentation by Mechanisms of Action
Some of the key mechanisms of action for influenza-marketed drugs are enzyme inhibitors, ion channel blockers, and biological factor activator. Enzyme inhibitor was the leading MoA in 2022.
SIT Marketed Drugs Analysis, by Mechanism of Action, 2022 (%)
For more MoA insights into SIT marketed drugs, download a free report sample
SIT Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for SIT marketed drugs are oral, injection, and inhalational. Oral was the most preferred route in 2022.
SIT Marketed Drugs Analysis, by Routes of Administration, 2022 (%)
For more RoA insights into the SIT marketed drugs, download a free report sample
SIT Marketed Drugs Segmentation by Molecule Type
Most of the marketed drugs for SIT are small molecules. Biologics is another significant molecule type in the marketed drugs for SIT.
SIT Marketed Drugs Analysis, by Molecule Type, 2022 (%)
For more molecule type insights into the SIT marketed drugs, download a free report sample
Leading Pipeline Drugs for SIT
Some of the leading pipeline drugs of SIT are nitazoxanide, DAS-181, naltrexone hydrochloride, AV-5080, CD-388, diltiazem, INNA-051, metenkefalin, Neumifil, PrEP-001, TG-1000, and ZSP-1273.
SIT Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for SIT pipeline drugs are enzyme inhibitor, antigen inhibitor, receptor agonist, ion channel blocker, receptor antagonist, enzyme activator, protein and peptide inhibitor, cells and cell organelle disrupter, toxin inhibitor, and transporter inhibitor. Enzyme inhibitor was the leading MoA in the pipeline in 2022.
SIT Pipeline Drugs Analysis, by Mechanisms of Action, 2022 (%)
For more MoA insights into the SIT pipeline drugs market, download a free report sample
SIT Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for SIT pipeline drugs are oral, inhalational, injection, and topical. Oral was the most preferred route of administration in 2022.
SIT Pipeline Drugs Analysis, by Routes of Administration, 2022 (%)
For more routes of administration insights for SIT pipeline drugs market, download a free report sample
SIT Pipeline Drugs Segmentation by Molecule Type
The key molecule types for the SIT pipeline drugs are small molecule, biologic, oligonucleotide, and polymer. Small molecule was the leading molecule type in 2022.
SIT Pipeline Drugs Analysis, by Molecule Types, 2022 (%)
For more molecule type insights into the SIT pipeline drugs market, download a free report sample
Top Sponsors in the SIT Marketed and Pipeline Drugs Market
Some of the top sponsors in the SIT marketed and pipeline drugs market are Roche, GlaxoSmithKline, FUJIFILM Toyama Chemical, Tecnofarma, Sun Pharma, Romark Laboratories, Ansun Biopharma, Alla Chem, Signia Therapeutics, TaiGen Biotechnology, Statera Biopharma, Cidara Therapeutics, and others. Among all the sponsors, Johnson & Johnson has sponsored the highest number of clinical trials of all the trials initiated in influenza in the past 10 years.
SIT Marketed Drugs Report Overview
|Key Mechanisms of Action||Enzyme Inhibitors, Ion Channel Blockers, and Biological Factor Activator|
|Key Routes of Administration||Oral, Injection, and Inhalational|
|Key Molecule Types||Small Molecule and Biologics|
SIT Pipeline Drugs Market Report Overview
|Key Mechanisms of Action||Enzyme Inhibitor, Antigen Inhibitor, Receptor Agonist, Ion Channel Blocker, Receptor Antagonist, Enzyme Activator, Protein and Peptide Inhibitor, Cells and Cell Organelle Disrupter, Toxin Inhibitor, and Transporter Inhibitor|
|Key Routes of Administration||Oral, Inhalational, Injection, and Topical|
|Key Molecule Types||Small Molecule, Biologic, Oligonucleotide, and Polymer|
|Top Sponsors (Marketed and
|Roche, GlaxoSmithKline, FUJIFILM Toyama Chemical, Tecnofarma, Sun Pharma, Romark Laboratories, Ansun Biopharma, Alla Chem, Signia Therapeutics, TaiGen Biotechnology, Statera Biopharma, Cidara Therapeutics, and Others|
SIT Marketed Drugs MoA Outlook
- Enzyme Inhibitors
- Ion Channel Blockers
- Biological Factor Activator
SIT Marketed Drugs RoA Outlook
SIT Marketed Drugs Molecule Types Outlook
- Small Molecule
SIT Pipeline Drugs MoA Outlook
- Enzyme Inhibitor
- Antigen Inhibitor
- Receptor Agonist
- Ion Channel Blocker
- Receptor Antagonist
- Enzyme Activator
- Protein and Peptide Inhibitor
- Cells and Cell Organelle Disrupter
- Toxin Inhibitor
- Transporter Inhibitor
SIT Pipeline Drugs RoA Outlook
SIT Pipeline Drugs Molecule Types Outlook
- Small Molecule
GlobalData’s SIT Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the SIT market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SIT market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Beijing Minhai Biotechnology
Development Center for Biotechnology
F. Hoffmann-La Roche
Fluart Innovative Vaccines
Institute of Virology Vaccines and Sera Torlak
Japan Vaccine Co
Johnson & Johnson
Merck & Co
Osaka City University
Scientific Research Institute for Biological Safety Problems
The Institute of Vaccines and Medical Biologicals
The National Institute of Allergy and Infectious Diseases
Table of Contents
1.2 Report Scope
1.3 List of Tables and Figures
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
5.1 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Geographic Overview
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis – Geographic Overview
7.16 Feasibility Analysis – Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11.2 Methodology – Sales Forecast
11.3 Methodology – Pricing and Reimbursement
11.4 Methodology – PTSR and LoA Analysis
11.5 About the Authors
11.6 Contact Us
Frequently asked questions
What are the key mechanisms of action for SIT marketed drugs?
The key mechanisms of action for SIT marketed drugs are enzyme inhibitors, ion channel blockers, and biological factor activator.
What are the key routes of administration for SIT marketed drugs?
The key routes of administration for SIT marketed drugs are oral, injection, and inhalational.
What are the key molecule types for SIT marketed drugs?
The key molecule types for SIT marketed drugs are small molecule and biologics.
What are the key mechanisms of action for SIT pipeline drugs?
The key mechanisms of action in the SIT pipeline drugs market are enzyme inhibitor, antigen inhibitor, receptor agonist, ion channel blocker, receptor antagonist, enzyme activator, protein and peptide inhibitor, cells and cell organelle disrupter, toxin inhibitor, and transporter inhibitor.
What are the key routes of administration for SIT pipeline drugs?
The key routes of administration in the SIT pipeline drugs market are oral, inhalational, injection, and topical.
What are the key molecule types for SIT pipeline drugs?
The key molecule types in the SIT pipeline drugs market are small molecule, biologic, oligonucleotide, and polymer.
Who are the top sponsors for the SIT marketed and pipeline drugs market?
Some of the top sponsors for the SIT marketed and pipeline drugs market are Roche, GlaxoSmithKline, FUJIFILM Toyama Chemical, Tecnofarma, Sun Pharma, Romark Laboratories, Ansun Biopharma, Alla Chem, Signia Therapeutics, TaiGen Biotechnology, Statera Biopharma, Cidara Therapeutics, and others.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.